摘要
目的研究塞来昔布(特异性环氧合酶-2抑制剂)增强胃癌化疗药疗效的分子机制。方法以3个浓度(10、50、150mmol.L-1)塞来昔布干预胃癌细胞BGC-823株48h,用RT-PCR法观察用药前后多药耐药(MDR)相关基因如MDR1、多药耐药相关蛋白(MRP)和谷光甘肽-S-转移酶π(GST-π)基因的表达变化。结果胃癌细胞BGC-823株存在内在多药耐药性,表现为有MRP和GST-π表达、无MDR1表达。塞来昔布干预后,MRP和GST-π均有不同程度下降(P<0.05或P<0.01)。结论塞来昔布可通过抑制MDR相关基因如MRP和GST-π起化疗增敏剂作用。
Objective To investigate the conceivable molecular mechanism of a specific eyelooxygenase - 2 inhibitor eeleeoxib on synergetie anti - tumor role in gastric cancer in vitro. Methods Gastric cell line BGC -823 was interfered by a specific eyelooxygenase inhibitor celeeoxib, 10,50 and 150 mmol · L^-1, respectively. The expression and changes of multidrug resistance (MDR) gene family was assessed by reverse transcription - polymerase chain reaction. Results MDR gene family was detected on gastric cancer cell line BGC -823, the positive expression were multidrug - associated protein (MRP) and glutathione - S - trans- ferases -π (GST -π) gene, but MDR1 gene was undeteetable. After treatment with eeleeoxib (concentration range of 10 - 150 mmol·L^-1 ), a significant down regulation of MRP and GST -π mRNA was observed ( P 〈 0.05 or P 〈 0.01 ). Conclusion By inhibiting the intrinsic multidrug resistance, eeleeoxib plays a synergetie anti -tumor role in chemotherapy drugs on gastric cancer cell line BGC -823.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2008年第3期237-239,共3页
The Chinese Journal of Clinical Pharmacology
关键词
胃肿瘤
塞来昔布
逆转录多聚酶链反应
多药耐药
stomach neoplasms
eeleeoxib
reverse transcription - poly- merase chain reaction
multidrug resistance